Clinical Trials
18 trialsNCT07124000 2026-06-01
DP-04
AstraZeneca
Recruiting
NCT06904365 2026-05-18
OvAR-Y
Washington University School of Medicine
Active not recruiting
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT06270706 2026-04-20
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
Phase 1 Recruiting
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT05858736 2026-04-09
PRESERVE-009
OncoC4, Inc.
Phase 1 Active not recruiting
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT06526819 2026-02-27
SMP-3124LP in Adults With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Phase 1/2 Recruiting
NCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT02408861 2026-01-21
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT04272034 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT05941507 2025-09-24
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Recruiting
NCT02628067 2025-09-22
KEYNOTE 158
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT03958240 2025-09-15
DECIDE
Institut Claudius Regaud
Phase NA Recruiting
NCT06582849 2025-08-26
EARN
Washington University School of Medicine
Phase NA Completed
NCT07118176 2025-08-12
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting